Padmanabh P. Bhatt
Net Worth

Last updated:

What is Padmanabh P. Bhatt net worth?

The estimated net worth of Dr. Padmanabh P. Bhatt is at least $13,576,909 as of 3 Dec 2024. He owns shares worth $398,484 as insider, has earned $5,609,825 from insider trading and has received compensation worth at least $7,568,600 in Supernus Pharmaceuticals, Inc..

What is the salary of Padmanabh P. Bhatt?

Dr. Padmanabh P. Bhatt salary is $582,200 per year as Chief Scientific Officer & Senior Vice President of Intellectual Property in Supernus Pharmaceuticals, Inc..

How old is Padmanabh P. Bhatt?

Dr. Padmanabh P. Bhatt is 68 years old, born in 1957.

What stocks does Padmanabh P. Bhatt currently own?

As insider, Dr. Padmanabh P. Bhatt owns shares in one company:

Company Title Shares Price per share Total value
Supernus Pharmaceuticals, Inc. (SUPN) Chief Scientific Officer & Senior Vice President of Intellectual Property 9,679 $41.17 $398,484

What does Supernus Pharmaceuticals, Inc. do?

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

SUPN logo
SUPN
Supernus Pharmaceuticals, Inc.
$41.17

Padmanabh P. Bhatt insider trading

Supernus Pharmaceuticals, Inc.

Dr. Padmanabh P. Bhatt has made 35 insider trades between 2012-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 62,366 units of SUPN stock on 13 Mar 2024. As of 3 Dec 2024 he still owns at least 9,679 units of SUPN stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 12,745 $25.3 $322,449
Sale
Common Stock 12,745 $36.68 $467,487
Option
Common Stock 8,750 $23.99 $209,913
Option
Employee Stock Option (Right to Buy) 21,495 $24.65 $529,744
Option
Performance Share Unit 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Common Stock 14,491 $25.3 $366,622
Option
Employee Stock Option (Right to Buy) 14,491 $25.3 $366,622
Sale
Common Stock 14,491 $35.31 $511,677
Option
Common Stock 400 $25.3 $10,120
Option
Employee Stock Option (Right to Buy) 400 $25.3 $10,120
Sale
Common Stock 400 $35.31 $14,124
Sale
Common Stock 12,364 $35.31 $436,573
Option
Common Stock 12,364 $25.3 $312,809
Option
Employee Stock Option (Right to Buy) 12,364 $25.3 $312,809
Option
Employee Stock Option (Right to Buy) 36,116 $12.98 $468,786
Option
Employee Stock Option (Right to Buy) 26,250 $23.99 $629,738
Sale
Common Stock 62,366 $33.79 $2,107,347
Option
Common Stock 36,116 $12.98 $468,786
Option
Common Stock 26,250 $23.99 $629,738
Option
Common Stock 3,884 $12.98 $50,414
Sale
Common Stock 3,884 $32.99 $128,133
Option
Employee Stock Option (Right to Buy) 3,884 $12.98 $50,414
Sale
Common Stock 5,000 $30.21 $151,050
Option
Common Stock 5,000 $9.13 $45,650
Option
Employee Stock Option (Right to Buy) 5,000 $9.13 $45,650
Option
Common Stock 2,500 N/A N/A
Option
Performance Share Unit 2,500 N/A N/A
Option
Performance Share Unit 750 N/A N/A
Option
Common Stock 750 N/A N/A
Option
Common Stock 4,826 $9.13 $44,061
Option
Employee Stock Option (Right to Buy) 4,826 $9.13 $44,061
Sale
Common Stock 4,826 $39.92 $192,639
Option
Common Stock 174 $9.13 $1,589
Option
Employee Stock Option (Right to Buy) 174 $9.13 $1,589
Sale
Common Stock 174 $39.9 $6,943
Option
Common Stock 5,000 $9.13 $45,650
Option
Employee Stock Option (Right to Buy) 5,000 $9.13 $45,650
Sale
Common Stock 5,000 $37.48 $187,415
Sale
Common Stock 6,800 $34.95 $237,653
Option
Employee Stock Option (Right to Buy) 6,800 $9.24 $62,832
Option
Common Stock 6,800 $9.24 $62,832
Option
Employee Stock Option (Right to Buy) 700 $9.24 $6,468
Option
Common Stock 700 $9.24 $6,468
Sale
Common Stock 700 $34.97 $24,480
Sale
Common Stock 4,393 N/A N/A
Option
Common Stock 295 N/A N/A
Sale
Common Stock 3,402 N/A N/A
Option
Employee Stock Option (Right to Buy) 295 N/A N/A
Option
Common Stock 7,205 N/A N/A
Sale
Common Stock 7,205 N/A N/A
Option
Employee Stock Option (Right to Buy) 7,205 N/A N/A
Sale
Common Stock 368 N/A N/A
Option
Employee Stock Option (Right to Buy) 7,868 $33.58 $264,231
Option
Employee Stock Option (Right to Buy) 7,868 N/A N/A
Option
Common Stock 7,868 N/A N/A
Option
Common Stock 7,868 $33.58 $264,231
Option
Common Stock 42,132 $25.01 $1,053,848
Option
Employee Stock Option (Right to Buy) 42,132 $25.01 $1,053,848
Option
Common Stock 42,132 N/A N/A
Sale
Common Stock 36,250 N/A N/A
Sale
Common Stock 36,250 $31.57 $1,144,304
Option
Employee Stock Option (Right to Buy) 42,132 N/A N/A
Option
Employee Stock Option (Right to Buy) 20,000 N/A N/A
Sale
Common Stock 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 20,000 N/A N/A
Sale
Common Stock 20,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 20,000 N/A N/A
Sale
Common Stock 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 3,709 N/A N/A
Sale
Common Stock 3,735 N/A N/A
Sale
Common Stock 2,556 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 2,500 N/A N/A
Sale
Common Stock 3,887 N/A N/A
Sale
Common Stock 1,613 N/A N/A
Sale
Common Stock 11,806 N/A N/A
Sale
Common Stock 30,762 N/A N/A
Sale
Common Stock 4,685 N/A N/A
Sale
Common Stock 9,553 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 37,500 N/A N/A
Option
Employee Stock Option (Right to Buy) 37,500 N/A N/A
Option
Employee Stock Option (Right to Buy) 12,500 N/A N/A
Option
Common Stock 18,000 N/A N/A
Sale
Common Stock 2,285 N/A N/A
Option
Employee Stock Option (Right to Buy) 25,000 N/A N/A
Option
Common Stock 25,000 N/A N/A
Option
Employee Stock Option (right to buy) 25,000 N/A N/A
Option
Common Stock 25,000 N/A N/A